Human immunodeficiency virus (HIV) controllers are patients who control viral replication without antiretroviral therapy \[[@OFV039C1]\]. We present the case of an HIV controller who had CD4 and CD8 coexpressed on 40% of his T cells. Although a recent study found that double-positive T cells had superior antiviral capacity in HIV-1 controllers \[[@OFV039C2]\], in this case, the CD4^+^CD8^+^ T cells did not have strong antiviral activity.

CASE PRESENTATION {#s2}
=================

The patient is a 62-year-old African American male with human immunodeficiency virus (HIV) infection diagnosed 12 years ago. His CD4 count was 711 cells/µL, and his viral load was 141 copies/mL plasma without antiretroviral therapy (ART) at diagnosis. His viral load remained undetectable to low (\<400 copies/mL), and although his absolute CD4 count was very high, his CD4^+^ T cell percentage was low and his CD8^+^ T cell percentage was elevated (Figure [1](#OFV039F1){ref-type="fig"}A). At year 3, it was noted that 26% of lymphocytes coexpressed CD4 and CD8 and the proportion eventually peaked at 40%. These cells were not reported before year 3, but the aggregate percentage of CD4^+^ and CD8^+^ T cells exceeded 100%, suggesting that CD4^+^CD8^+^ cells had always been present. A malignancy workup included a polymerase chain reaction (PCR) for clonal T cell rearrangement (negative), fluorescent in situ hybridization for B-cell chronic lymphocytic leukemia (negative), and cytogenetics (normal chromosomes). Human T-lymphotropic virus type-1 serology was negative. Figure 1.Percentage of different T cell populations over time in the subject (A). Flow cytometry showing the large population of CD4^+^CD8^+^ T cells (B). Comparison of activated (C) and effector memory (EM; D) CD8^+^ T cells in the subject compared with healthy donors (HD), untreated viremic patients, patients on antiretroviral therapy (ART), and human immunodeficiency virus controllers (HC). The percentage of CD4^+^CD8^+^ T cells was too low in the other patients for a meaningful comparison to be performed. Percentage of cells that expressed interferon-γ or tumor necrosis factor-α alone or in combination after stimulation with anti-CD3 and anti-CD28 monoclonal antibodies.

Flow cytometry showed that the density of CD4 was lower on CD4^+^CD8^+^ T cells than on CD4^+^ T cells (Figure [1](#OFV039F1){ref-type="fig"}B). Because HIV infection results in down-regulation of CD4, we measured the frequency of HIV infection with semiquantitative PCR. Infection was detected in 0.01% of CD4^+^ T cells but \<0.001% of CD4^+^CD8^+^ cells (Table [1](#OFV039TB1){ref-type="table"}); therefore, double-positive cells were not a major infection target. Consistent with this finding, expression of CCR5 and CXCR4 was lower in CD4^+^CD8^+^ T cells than in CD4^+^ T cells, and there was less viral entry of CD4^+^CD8^+^ T cells than CD4^+^ T cells after spinoculation with CCR5-tropic and CXCR4-tropic viruses (Table [1](#OFV039TB1){ref-type="table"}). Table 1.Features of T Cell SubsetsCD4^+^ T CellsCD8^+^ T CellsCD4^+^CD8^+^ T CellsT cell phenotype Activated (CD38^+^/HLA-DR^+^)8%49%53% Naive (CCR7^+^/CD45RA^+^)9%2%1% Terminal Effector (CCR7^−^/CD45RA^+^)0%18%2% Central memory (CCR7^+^/CD45RA^−^)31%2%1% Effector memory (CCR7^−^/CD45RA^−^)18%35%55%HIV-1 susceptibility % infected cells (PCR analysis)0.01%NA\<0.001% CCR5 positive35%25%15% CXCR4 positive88%59%76% % CCR5-tropic virus entry27%0.3%6% % CXCR4-tropic virus entry20%0.4%7%Polyclonal T cell responses IFN-γ and/or TNF-α expression: Unstimulated cells0%0.5%0.4% IFN-γ and/or TNF-α expression: PHA-stimulated cells11.9%30.4%44.8%IFN-γ and/or TNF-α expression: CD3/CD28-stimulated cells25.9%40.9%39.1% IFN-γ and/or TNF-α expression: PMA/ionomycin-stimulated cells72.5%78.3%69.4%HIV-1-specific responses TNF-α expression: Unstimulated cells0.4%0.1%0.1% TNF-α expression: Gag-stimulated cells5.2%7%6.1% TNF-α, IFN-γ, IL-2 expression: Gag-stimulated cells\<0.1%\<0.1%\<0.1% % Inhibition of HIV-1 replication: Day 5NA29%0%[^3]

A much larger fraction of CD8^+^ and CD4^+^CD8^+^ T cells was activated compared with CD4^+^ T cells as measured by HLA-DR/CD38^+^ expression (Table [1](#OFV039TB1){ref-type="table"}). The percentage of activated CD8^+^ T cells was comparable to that seen in untreated individuals and higher than that in treated patients, HIV controllers, and uninfected individuals (Figure [1](#OFV039F1){ref-type="fig"}C).

CD4^+^CD8^+^ and CD8^+^ T cell fractions contained high levels of effector memory cells (Table [1](#OFV039TB1){ref-type="table"}) that exceeded the percentage seen in healthy donor and HIV-infected subjects (Figure [1](#OFV039F1){ref-type="fig"}D). The CD4^+^CD8^+^ T cells, CD4^+^ T cells and CD8^+^ T cell produced comparable levels of cytokines in response to polyclonal stimulation (Table [1](#OFV039TB1){ref-type="table"}), but the pattern of the cytokine production in CD4^+^CD8^+^ T cells was more similar to CD8^+^ T cells than CD4^+^ T cells (Figure [1](#OFV039F1){ref-type="fig"}E). To determine whether the cells were HIV-1 specific, they were stimulated with HIV-1 antigens. A similar proportion of all 3 cell populations expressed TNF-α in response to stimulation with Gag peptides (Table [1](#OFV039TB1){ref-type="table"}). In contrast to a prior study in which CD4^+^CD8^+^ T cells were often multifunctional \[[@OFV039C2]\], \<0.1% of CD4^+^, CD8^+^, and CD4^+^CD8^+^ simultaneously expressed TNF-α, IFN-γ, and IL-2 (Table [1](#OFV039TB1){ref-type="table"}). Furthermore, although CD8^+^ T cells had a modest inhibitory effect on viral replication, CD4^+^CD8^+^ T had no detectable effect (Table [1](#OFV039TB1){ref-type="table"}).

CONCLUSIONS {#s3}
===========

We present the case of an HIV controller with a very large, persistent population of CD4^+^CD8^+^ T cells (15%--40%). There is a prior report of an HIV-infected individual with progressive disease who had elevated CD4^+^CD8^+^ T cells (approximately 7.5%) over 8 years \[[@OFV039C3]\]. In that case, CD4^+^CD8^+^ T cells had a low CD8 density and were phenotypically similar to CD4^+^ cells, whereas in our case, the CD4^+^CD8^+^ T cells are similar to CD8^+^ T cells based on the cytokine expression pattern and activation and memory markers. Although some studies suggest that CD4^+^CD8^+^ T cells have enhanced antiviral activity \[[@OFV039C2], [@OFV039C4]\], this was not observed here.

Although we were not able to determine the etiology of the mutual expression of CD4 and CD8 on T cells, flow cytometry revealed that the majority of these CD4^+^CD8^+^ T cells were effector memory cells with an activated phenotype. Human immunodeficiency virus controllers generally have higher levels of activated CD8^+^ T cells \[[@OFV039C5]\], elevated inflammatory biomarkers \[[@OFV039C6], [@OFV039C7]\], and higher rates of atherosclerosis \[[@OFV039C8], [@OFV039C9]\] compared with treated and uninfected individuals. The significance of this inflammation is an active area of investigation. A recent study reported HIV controllers have higher rates of hospitalization than treated patients \[[@OFV039C10]\]. Preliminary studies suggest that ART decreases immune activation in some HIV controllers \[[@OFV039C11]--[@OFV039C13]\]. Randomized controlled trials are needed to determine the impact of ART and/or anti-inflammatory treatment in HIV controllers.
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